Paris-headquartered Onxeo (Euronext Paris: ONXEO) has divested two legacy products, Sitavig (acyclovir) and Loramyc (miconazole), to another French firm, privately-held Vectans Pharma.
Onxeo, which developed Sitavig and Loramyc for the treatment of labial herpes and oropharyngeal candidiasis, respectively, said the products are “no longer at the heart of our strategy, dedicated to the development of innovative drugs in orphan oncology.”
The products have already been licensed to several international distributors and have reached various development stages, from ongoing registration to market authorization and commercialization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze